ASX:CPH Creso Pharma (CPH) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free CPH Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Creso Pharma alerts: Email Address Ad InvestorPlaceThe Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story. About Creso Pharma Stock (ASX:CPH)Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates, processes, and sells cannabis products, as well as supplies cannabis retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.Read More Ad InvestorPlaceThe Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story. CPH Stock News HeadlinesJune 5, 2023 | msn.comCreso Pharma subsidiary Mernova Medicinal appoints consultant to expedite cannabis exports to Australia and EuropeMay 25, 2023 | hk.finance.yahoo.comCreso Pharma Insiders Lose Out As Stock Sinks To AU$0.009May 5, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...May 25, 2023 | finance.yahoo.comCreso Pharma Insiders Lose Out As Stock Sinks To AU$0.009 \May 19, 2023 | proactiveinvestors.comCreso Pharma raises A$2.5 million, streamlines balance sheet for growth strategyMay 9, 2023 | msn.comCreso’s US subsidiary Sierra Sage Herbs signs deal with Groupon; significantly increases potential market sizeMay 7, 2023 | proactiveinvestors.comCreso Pharma gains Supreme Court green light for Health House acquisitionApril 30, 2023 | proactiveinvestors.comCreso Pharma subsidiary secures new purchase orders and expands into AlbertaMay 5, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...March 5, 2023 | proactiveinvestors.comCreso Pharma boosts balance sheet through A$2.5 million convertible note issueMarch 3, 2023 | finance.yahoo.comCreso Pharma Full Year 2022 Earnings: AU$0.022 loss per share (vs AU$0.027 loss in FY 2021)February 26, 2023 | nz.finance.yahoo.comCreso Pharma Limited (CPH.AX)February 16, 2023 | proactiveinvestors.comCreso Pharma boosts finances for marketing push into US, psilocybin trial, with $2 million placementFebruary 8, 2023 | finance.yahoo.comHalucenex Life Sciences Inc. targets Australian market following landmark TGA decisionJanuary 29, 2023 | proactiveinvestors.com.auCreso Pharma looks to acquire baby product company Abby and Finn; to streamline finance structureJanuary 9, 2023 | proactiveinvestors.com.auCreso Pharma draws additional A$500,000 on funding facility; shareholders approve A$2 million in placement participation by directorsNovember 22, 2022 | fool.com.auRemember ASX cannabis shares? Well, this one is rocketing 50% todaySeptember 8, 2022 | fool.com.auCannabis company Creso Pharma up 36% on takeover approachAugust 13, 2022 | fool.com.auWhy these 4 ASX shares are ending the week with strong gainsJuly 19, 2022 | fool.com.auWhy the Creso Pharma Ltd share price has bolted higher todayJune 13, 2022 | fool.com.auWhy the Creso Pharma Ltd share price jumped 7% on MondayJune 13, 2022 | fool.com.auWhy the Creso Pharma Ltd share price climbed 5% higher todayMay 23, 2022 | finance.yahoo.comEven after rising 14% this past week, Creso Pharma (ASX:CPH) shareholders are still down 87% over the past three yearsFebruary 10, 2022 | msn.comCreso Pharma welcomes legendary Canadian founder, M&A legend and CBD entrepreneur Bruce LintonFebruary 4, 2022 | benzinga.comAustralian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage HerbsFebruary 3, 2022 | msn.comThe Creso Pharma (ASX:CPH) share price jumped 6% today. Here’s whyDecember 3, 2021 | finance.yahoo.comShareholders in Creso Pharma (ASX:CPH) are in the red if they invested three years agoSee More Headlines Receive CPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Creso Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolASX:CPH CUSIPN/A CIKN/A Webwww.cresopharma.com Phone61 2 8067 8606FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-130.99% Return on Assets-35.93% Debt Debt-to-Equity Ratio29.92 Current Ratio0.76 Quick Ratio1.41 Sales & Book Value Annual Sales$8.92 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares2,570,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.62 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Boaz Wachtel M.A. (Age 63)M.D., MBA, Co-Founder & Non-Exec. Chairman Comp: $97.14kMr. Christopher GrundyChief Financial OfficerMr. William Lay B.Com.Group CEO, MD & DirectorDr. Gian TreppCommercial & Marketing DirectorMs. Micheline MacKay B.Sc.M.Sc., P.M.P., MD & Exec. DirectorMs. Jodi ScottExec. Director & Pres of US OperationsMs. Erlyn Saromines Dawson A.C.I.S.ACIS, AGIA, B.Com., BCom., GradDipACG, Joint Company Sec.Mr. Winton William Willesee C.P.A. (Age 53)GAICD, MAICD, MCom, Joint Company Sec. Dr. Simon H. W. Buckingham (Age 61)Consultant Hon. Brian WalkerStrategic Consultant & Chair of Scientific Advisory CommitteeMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors This page (ASX:CPH) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe #1 Investment of the Decade… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Creso Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
